Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q1 2024 vs. Q4 2023
How the institutions holding Cidara Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 51 | 50 | −1 |
| Shares | 23.2M | 22.1M | −1.12M (−4.8%) |
| Value | $18.4M | $20.3M | +$1.88M (+10.2%) |
New holders (7)
Institutions that held Cidara Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| West Michigan Advisors, LLC | 135,000 | $124.2K | 0.04% |
| Citadel Advisors LLC | 84,536 | $77.8K | 0.00% |
| Two Sigma Investments, LP | 67,245 | $61.9K | 0.00% |
| FNY Investment Advisers, LLC | 56,600 | $52.0K | 0.03% |
| Mariner, LLC | 10,000 | $9.20K | 0.00% |
| UBS Group AG | 4,695 | $4.32K | 0.00% |
| Simplex Trading, LLC | 525 | $0 | 0.00% |
Sold out (8)
Institutions that held Cidara Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Nantahala Capital Management, LLC | 1,546,745 | $1.23M |
| Bank of New York Mellon Corp | 126,540 | $100.5K |
| Virtu Financial LLC | 95,450 | $76.0K |
| Two Sigma Securities, LLC | 36,681 | $29.1K |
| Aveo Capital Partners, LLC | 22,502 | $17.9K |
| Susquehanna International Group, LLP | 12,886 | $10.2K |
| Bank of America Corp | 53 | $42 |
| Royal Bank of Canada | 246 | $0 |